Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.70 |
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12182065 | 1.00 | RXRA (0.70) | RXRAPPARGCYP1A2MAPTMAPK1 | |
| SCHEMBL18244654 | 1.00 | RXRA (0.70) | RXRAPPARGCYP1A2MAPTMAPK1 | |
| SCHEMBL18255113 | 0.90 | RXRA (0.56) | RXRAPPARGEGFR | |
| SCHEMBL30389738 | 0.87 | RXRA (0.67) | RXRAPPARGMAPTTDP1EGFR | |
| SCHEMBL18245004 | 0.87 | RXRA (0.67) | RXRAPPARGMAPTTDP1EGFR | |
| SCHEMBL18245005 | 0.87 | RXRA (0.67) | RXRAPPARGMAPTTDP1EGFR | |
| SCHEMBL24101806 | 0.82 | RXRA (0.61) | RXRAPPARGEGFR | |
| SCHEMBL30486797 | 0.82 | RXRA (0.61) | RXRAPPARGEGFR | |
| SCHEMBL17118993 | 0.81 | RXRA (0.76) | RXRAPPARGCYP1A2MAPTMAPK1 | |
| SCHEMBL30390311 | 0.81 | RXRA (0.76) | RXRAPPARGCYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234909-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NUCMITO PHARMACEUTICALS CO. LTD. (CN) | 2023-07-27 | — | — | US | claimed |
| CN-116472034-A | Indene compound, pharmaceutical composition thereof and therapeutic application thereof | 藤济(厦门)生物医药科技有限公司 | 2023-07-21 | — | — | CN | claimed |
| EP-4165009-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Nucmito Pharmaceuticals Co., Ltd. (CN) | 2023-04-19 | — | — | EP | claimed |
| CN-116472034-A | Indene compound, pharmaceutical composition thereof and therapeutic application thereof | 藤济(厦门)生物医药科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4165009-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Nucmito Pharmaceuticals Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234909-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | MMP1, IDO1, COL1A1 | RXRA 860/4885PPARG 378/4885CYP1A2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.